8-K
Vycor Medical Inc (VYCO)
UNITEDSTATESSECURITIES AND EXCHANGE COMMISSION
WASHINGTON,D.C. 20549
FORM8-K
CURRENTREPORT
PURSUANT TO SECTION 13 OR 15(D) OFTHE SECURITIES EXCHANGE ACT OF 1934
Dateof Report (Date of earliest event reported): March 19, 2021
VycorMedical, Inc.
(Exact Name of Registrant as Specified in its Charter)
| Delaware | 001-34932 | 20-3369218 |
|---|---|---|
| (State<br> or Other Jurisdiction<br><br> <br>of<br> Incorporation) | (Commission<br><br> <br>File<br> No.) | (I.R.S.<br> Employer<br><br> <br>Identification<br> No.) |
| 951<br> Broken Sound Parkway, Suite 320, Boca Raton, FL | 33487 | |
| --- | --- | |
| (Address<br> of Principal Executive Offices) | (Zip<br> Code) |
Registrant’s telephone number, including area code: (561) 558-2020
Securities Registered Pursuant to Section 12(b) of the Act:
| Title<br> of Each Class | Trading<br> Symbol | Name<br> of Each Exchange on which registered |
|---|---|---|
| Common<br> Stock, par value $0.0001 | VYCO | OTCQB |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| [ ] | Written<br> communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|---|---|
| [ ] | Soliciting<br> material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| [ ] | Pre-commencement<br> communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| [ ] | Pre-commencement<br> communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
TABLEOF CONTENTS
| Item<br> 5.02 | Departure<br> of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;<br> Compensatory Arrangements with Certain Officers |
|---|---|
| SIGNATURES | |
| Item5.02 | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements with Certain Officers |
| --- | --- |
On March 19, 2021 the Company’s Board of Directors accepted the tendered resignations of Steven Girgenti and Lowell Rush as Directors of the Company for personal reasons. The resignations are effective as of April 1, 2021. The Board expressed its appreciation for Messrs. Girgenti’s and Rush’s many years of service to the Company. There were no disagreements between the Company and either of Messrs. Girgenti and/or Rush on any matters.
SIGNATURES
Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Vycor Medical, Inc. | |
|---|---|
| By: | /s/ Peter C. Zachariou |
| Name: | Peter<br> C. Zachariou |
| Title: | Chief<br> Executive Officer |
| Dated:<br> March 22, 2021 |